loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Balixafortide

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Balixafortide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Spexis announces promising pre-clinical data with balixafortide in combination
    Spexis announces promising pre-clinical data with balixafortide in combination

    13 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2022/12/13/2572358/0/en/Spexis-announces-promising-pre-clinical-data-with-balixafortide-in-combination-with-various-therapies-on-the-market-for-treating-B-cell-lymphomas.html

    GLOBENEWSWIRE
    13 Dec 2022
    Share Share
    Spexis announces promising data with balixafortide with various therapies
    Spexis announces promising data with balixafortide with various therapies

    13 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/12/13/2572358/0/en/Spexis-announces-promising-pre-clinical-data-with-balixafortide-in-combination-with-various-therapies-on-the-market-for-treating-B-cell-lymphomas.html

    GLOBENEWSWIRE
    13 Dec 2022
    Share Share
    Spexis announces positive renal impairment trial results with balixafortide
    Spexis announces positive renal impairment trial results with balixafortide

    22 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/22/2520691/0/en/Spexis-announces-positive-renal-impairment-clinical-trial-results-with-balixafortide.html

    GLOBENEWSWIRE
    22 Sep 2022
    Share Share
    Polyphor provides update on the future of the FORTRESS study of balixafortide
    Polyphor provides update on the future of the FORTRESS study of balixafortide

    19 Jul 2021

    // BLOOMBERG

    https://www.bloomberg.com/press-releases/2021-07-16/eqs-adhoc-polyphor-provides-update-on-the-future-of-the-fortress-study-of-balixafortide-and-announces-initial-restructuring

    BLOOMBERG
    19 Jul 2021
    Share Share
    Polyphor flops a phase 3, jeopardizing its future
    Polyphor flops a phase 3, jeopardizing its future

    28 Jun 2021

    // FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/polyphor-flops-a-phase-3-jeopardizing-its-future-as-shares-more-than-halved

    FIERCEBIOTECH
    28 Jun 2021
    Share Share
    Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide
    Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide

    28 Jun 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/06/28/2253544/0/en/Polyphor-Provides-Update-on-the-Phase-III-FORTRESS-Study-of-Balixafortide-in-Patients-With-Advanced-HER2-Negative-Breast-Cancer.html

    GLOBENEWSWIRE
    28 Jun 2021
    Share Share